Drug Regulation of Activity NLR-Associated Excitation

O.Ye. Abaturov, A.P. Volosovets, Ye.I. Yulish

Abstract


The review presents the properties of drugs being developed and used in clinical practice that modulate the activity of NLR, caspase-1 and IL-1F2(IL-1β).

Keywords


therapy; infectious process; NLR.

References


Announ N., Palmer G., Guerne P.A., Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure // Joint Bone Spine. — 2009. — Vol. 76, № 4. — P. 424-426. doi: 10.1016/j.jbspin.2009.01.001.

Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety // Eur. J. Pediatr. — 2011. — Vol. 170, № 2. — P. 157-167. doi: 10.1007/s00431-010-1238-z.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associa­ted periodic syndrome (CAPS) / J.B. Kuemmerle-Deschner, E. Ramos, N. Blank, J. Roesler, S.D. Felix, T. Jung, K. Stricker, A. Chakraborty, S. Tannenbaum, A.M. Wright, C. Rordorf // Arthritis Res. Ther. — 2011. — Vol. 13, № 1. — P. R34. doi: 10.1186/ar3266.

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis / A. So, M. De Meulemeester, A. Pikhlak, A.E. Yücel, D. Richard, V. Murphy, U. Arulmani, P. Sallstig, N. Schlesinger // Arthritis Rheum. — 2010, Jun 8.

Church L.D., Cook G.P., McDermott M.F. Primer: inflammasomes and interleukin 1 in inflammatory disorders // Nature Clinical Practice Rheumatology. — 2008. — Vol. 4, № 1. — P. 34-42. doi: 10.1038/ncprheum0681.

Church L.D., McDermott M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders // Curr. Opin. Mol. Ther. — 2009. — Vol. 11, № 1. — P. 81-89.

Cook G.P., Savic S., Wittmann M., McDermott M.F. The NLRP3 inflammasome, a target for therapy in diverse disease states // Eur. J. Immunol. — 2010. — Vol. 40, № 3. — P. 631-634. doi: 10.1002/eji.200940162.

Correa R.G., Milutinovic S., Reed J.C. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases // Biosci Rep. — 2012. — Vol. 32, № 6. — P. 597-608. doi: 10.1042/BSR20120055.

Crittenden D.B., Pillinger M.H. New therapies for gout // Annu. Rev. Med. — 2013. — Vol. 64. — P. 325-337. doi: 10.1146/annurev-med-080911-105830.

Dhimolea E. Canakinumab // MAbs. — 2010. — Vol. 2, № 1. — P. 3-13. PMC2828573.

Dinarello C.A. IL-1: Discoveries, controversies and future directions // Eur. J. Immunol. — 2010. — Vol. 40, № 3. — P. 595-653. doi: 10.1002/eji.201040319.

Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors / R.G. Correa, P.M. Khan, N. Askari, D. Zhai, M. Gerlic, B. Brown, G. Magnuson, R. Spreafico, S. Albani, E. Sergienko, P.W. Diaz, G.P. Roth, J.C. Reed // Chem. Biol. — 2011. — Vol. 18, № 7. — P. 825-832. doi: 10.1016/j.chembiol.2011.06.009.

Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study / H. Lachman, I. Kone-Paut, J. Kuemmerle-Deschner, K. Leslie, E. Hachulla, P. Quartier, X. Gitton, N. Patel, K. Lheritier, P.N. Hawkins// J. Allergy Clin. Immunol. — 2009. — Vol. 123, № 3. — P. 732.

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies / H.M. Hoffman, M.L. Throne, N.J. Amar, M. Sebai, A.J. Kivitz, A. Kavanaugh, S.P. Weinstein, P. Belomestnov, G.D. Yancopoulos, N. Stahl, S.J. Mellis // Arthritis Rheum. — 2008. — Vol. 58, № 8. — P. 2443-2452. doi: 10.1002/art.23687.

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra / L. Lepore, G. Paloni, R. Caorsi, M. Alessio, D. Rigante, N. Ruperto, M. Cattalini, A. Tommasini, F. Zulian, A. Ventura, A. Martini, M. Gattorno // J. Pediatr. — 2010. — Vol. 157, № 2. — P. 310-315. doi: 10.1016/j.jpeds.2010.02.040.

Goldbach-Mansky R. Blocking interleukin-1 in rheumatic di­seases // Ann. NY Acad. Sci. — 2009. — Vol. 1182. — P. 111-123. doi: 10.1111/j.1749-6632.2009.05159.x.

Gratton S.B., Scalapino K.J., Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation // Arthritis Rheum. — 2009. — Vol. 61, № 9. — P. 1268-1270. doi: 10.1002/art.24694.

Gunosewoyo H., Kassiou M. P2X purinergic receptor ligands: recently patented compounds // Expert. Opin. Ther. Pat. — 2010. — Vol. 20, № 5. — P. 625-646. doi: 10.1517/13543771003702424.

Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation / P.M. Khan, R.G. Correa, D.B. Divlianska, S. Peddibhotla, E.H. Sessions, G. Magnuson, B. Brown, E. Suyama, H. Yuan, A. Mangravita-Novo, M. Vicchiarelli, Y. Su, S. Vasile, L.H. Smith, P.W. Diaz, J.C. Reed, G.P. Roth // ACS Med. Chem. Lett. — 2011. — Vol. 2, № 10. — P. 780-785.

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemiconset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France / T. Lequerre, P. Quartier, D. Rosellini, F. Alaoui, M. De Bandt, O. Mejjad, I. Kone-Paut, M. Michel, E. Dernis, M. Khellaf, N. Limal, C. Job-Deslandre, B. Fautrel, X. Le Loët, J. Sibilia // Ann. Rheum. Dis. — 2008. — Vol. 67, № 3. — P. 302-308. doi:10.1136/ard.2007.076034.

Interleukin-1-receptor antagonist in type 2 diabetes mellitus / C.M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J.A. Ehses, B. Seifert, T. Mandrup-Poulsen, M.Y. Donath // N. Engl. J. Med. — 2007. — Vol. 356, № 15. — P. 1517-1526. doi: 10.1056/NEJMoa065213.

Kapur S., Bonk M.E. Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes // PT. — 2009. — Vol. 34, № 3. — P. 138-141. PMC2697082.

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity / M.K. Roell, H. Issafras, R.J. Bauer, K.S. Michelson, N. Mendoza, S.I. Vanegas, L.M. Gross, P.D. Larsen, D.H. Bedinger, D.J. Bohmann, G.H. Nonet, N. Liu, S.R. Lee, M. Handa, S.S. Kantak, A.H. Horwitz, J.J. Hunter, A.M. Owyang, A.M., Mirza J.A. Corbin, M.L. White // J. Biol. Chem. — 2010. — Vol. 285, № 27. — P. 20607-20614. doi: 10.1074/jbc.M110.115790.

Kubota T., Koike R. Cryopyrin-associated periodic syndromes: background and therapeutics // Mod. Rheumatol. — 2010. — Vol. 20, № 3. — P. 213-221. doi: 10.1007/s10165-009-0271-0.

Lyseng-Williamson K.A. Canakinumab: a guide to its use in acute gouty arthritis flares // BioDrugs. — 2013. — Vol. 27, № 4. — P. 401-6. doi: 10.1007/s40259-013-0037-2.

McDermott M.F. Rilonacept in the treatment of chronic inflammatory disorders // Drugs Today (Barc). — 2009. — Vol. 45, № 6. — P. 423-430. doi: 10.1358/dot.2009.45.6.1378935.

Mitroulis I., Skendros P., Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome // Eur. J. Intern. Med. — 2010. — Vol. 21, № 3. — P. 157-163. doi: 10.1016/j.ejim.2010.03.005.

Moltó A., Olivé A. Anti-IL-1 molecules: new comers and new indications // Joint. Bone Spine. — 2010. — Vol. 77, № 2. — P. 102-107. doi: 10.1016/j.jbspin.2009.10.011.

Results of a Phase II clinical trial of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatiod arthritis (CREATE study) / McInnes, I.B. et al. // ACR/ARHP Annual Scientific Meeting, presentation 2085. — 2007.

Stahl N., Radin A., Mellis S. Rilonacept-CAPS and beyond // Ann. NY. Acad. Sci. — 2009. — Vol. 1182. — P. 124-134. doi: 10.1111/j.1749-6632.2009.05074.x.

XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model / A.M. Owyang, K. Maedler, L. Gross, J. Yin, L. Esposito, L. Shu, J. Jadhav, E. Domsgen, J. Bergemann, S. Lee, S. Kantak // Endocrinology. — 2010. — Vol. 151, № 6. — P. 2515-2527. doi: 10.1210/en.2009-1124.

Young M.T. P2X receptors: dawn of the post-structure era // Trends Biochem. Sci. — 2010. — Vol. 35, № 2. — P. 83-90. doi: 10.1016/j.tibs.2009.09.006.




DOI: https://doi.org/10.22141/2224-0551.7.58.2014.75837

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта